{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T04:17:47Z","timestamp":1778991467153,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,10,14]],"date-time":"2005-10-14T00:00:00Z","timestamp":1129248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00198-005-2001-6","type":"journal-article","created":{"date-parts":[[2005,10,13]],"date-time":"2005-10-13T13:33:22Z","timestamp":1129210402000},"page":"2063-2068","source":"Crossref","is-referenced-by-count":76,"title":["Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate"],"prefix":"10.1007","volume":"16","author":[{"given":"J. D.","family":"Ringe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Dorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,10,14]]},"reference":[{"key":"2001_CR1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1053\/sarh.2002.50014","volume":"32","author":"Arayssi","year":"2003","unstructured":"Arayssi TK, Tawbi HA, Usta IM, Hourani MH (2003) Calcitonin in the treatment of transient osteoporosis of the hip. Semin Arthritis Rheum 32:388\u2013397","journal-title":"Semin Arthritis Rheum"},{"key":"2001_CR2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S8756-3282(03)00164-9","volume":"33","author":"Berger","year":"2003","unstructured":"Berger CE, Kr\u00f6ner AH, Minai-Pour MB, Ogris E, Engel A (2003) Biochemical markers of bone metabolism in bone marrow edema syndrome of the hip. Bone 33:346\u2013351","journal-title":"Bone"},{"key":"2001_CR3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S8756-3282(02)00812-8","volume":"31","author":"Varenna","year":"2002","unstructured":"Varenna M, Zucchi F, Binelli L, Failoni S, Gallazzi M, Sinigaglia L (2002) Intravenous pamidronate in the treatment of transient osteoporosis of the hip. Bone 31:96\u2013101","journal-title":"Bone"},{"key":"2001_CR4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0049-0172(92)90003-V","volume":"22","author":"Schapira","year":"1992","unstructured":"Schapira D (1992) Transient osteoporosis of the hip. Semin Arthritis Rheum 22:98\u2013105","journal-title":"Semin Arthritis Rheum"},{"key":"2001_CR5","first-page":"187","volume":"46","author":"Balakrishnan","year":"2003","unstructured":"Balakrishnan A, Schemitsch EH, Pearce D, McKee MD (2003) Distinguishing transient osteoporosis of the hip from avascular necrosis. Can J Surg 46:187\u2013192","journal-title":"Can J Surg"},{"key":"2001_CR6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2106\/00004623-199504000-00017","volume":"77","author":"Guerra","year":"1995","unstructured":"Guerra JJ, Steinberg ME (1995) Distinguishing transient osteoporosis from avascular necrosis of the hip. J Bone Joint Surg Am 77:616\u2013624","journal-title":"J Bone Joint Surg Am"},{"key":"2001_CR7","first-page":"107","volume":"21","author":"Schapira","year":"2003","unstructured":"Schapira D, Braun Moscovici Y, Gutierrez G, Nahir AM (2003) Severe transient osteoporosis of the hip during pregnancy. Successful treatment with intravenous bisphosphonates. Clin Exp Rheumatol 21:107\u2013110","journal-title":"Clin Exp Rheumatol"},{"key":"2001_CR8","first-page":"35","volume":"18","author":"McCarthy","year":"1998","unstructured":"McCarthy EF (1998) The pathology of transient regional osteoporosis. Iowa Orthop J 18:35\u201342","journal-title":"Iowa Orthop J"},{"key":"2001_CR9","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1517\/14656566.4.12.2253","volume":"4","author":"Miller","year":"2003","unstructured":"Miller PD (2003) Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. Expert Opin Pharmacother 4:2253\u20132258","journal-title":"Expert Opin Pharmacother"},{"key":"2001_CR10","doi-asserted-by":"crossref","unstructured":"Langston AL, Ralston SH (2004) Management of Paget\u2019s disease of bone. Rheumatology (Oxford) 43:955\u2013959","DOI":"10.1093\/rheumatology\/keh243"},{"key":"2001_CR11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s005200100292","volume":"10","author":"Body","year":"2002","unstructured":"Body JJ, Mancini I (2002) Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10:399\u2013407","journal-title":"Support Care Cancer"},{"key":"2001_CR12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00402-003-0532-x","volume":"123","author":"Miltner","year":"2003","unstructured":"Miltner O, Niedhardt C, Piroth W, Weber M, Siebert CH (2003) Transient osteoporosis of the navicular bone in a runner. Arch Orthop Trauma Surg 123:505\u2013508","journal-title":"Arch Orthop Trauma Surg"},{"key":"2001_CR13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00002060-199803000-00011","volume":"77","author":"Samdani","year":"1998","unstructured":"Samdani A, Lachmann E, Nagler W (1998) Transient osteoporosis of the hip during pregnancy: a case report. Am J Phys Med Rehabil 77:153\u2013156","journal-title":"Am J Phys Med Rehabil"},{"key":"2001_CR14","first-page":"282","volume":"16","author":"Perucca","year":"1992","unstructured":"Perucca R, Micek J (1992) Treatment of infusion-related phlebitis: review and nursing protocol. J Intraven Nurs 16:282\u2013286","journal-title":"J Intraven Nurs"},{"key":"2001_CR15","first-page":"1494","volume":"8","author":"Parker","year":"1999","unstructured":"Parker L (1999) IV devices and related infections: causes and complications. Br J Nurs 8:1494\u20131498","journal-title":"Br J Nurs"},{"key":"2001_CR16","unstructured":"Bandeira F, Kayath M, Marques-Neto J, et al (2003) Patient\u2019s clinical features and compliance associated with raloxifene or alendronate after a 6-month observational Brazilian study (abstract). J Bone Miner Res 18[Suppl 2]:M352"},{"key":"2001_CR17","unstructured":"Lombas C, Hakim C, Zanchetta J (2000) Compliance with alendronate treatment in an osteoporosis clinic (abstract) J Bone Miner Res 16[Suppl 1]:529"},{"key":"2001_CR18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","volume":"14","author":"Hamilton","year":"2003","unstructured":"Hamilton B, McCoy K, Taggert H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259\u2013262","journal-title":"Osteoporos Int"},{"key":"2001_CR19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","volume":"6","author":"M","year":"1991","unstructured":"M\u00fchlbauer RC, Bauss F, Schenk R, et al (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003\u20131011","journal-title":"J Bone Miner Res"},{"key":"2001_CR20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR, et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405","journal-title":"Ann Oncol"},{"key":"2001_CR21","first-page":"46","volume":"22","author":"Tripathy","year":"2003","unstructured":"Tripathy D, Body JJ, Diel I, et al (2003) Oral daily ibandronate: efficacy in reducing skeletal complications in patients with metastatic bone disease from breast cancer (abstract). Proc Am Soc Clin Oncol 22:46","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2001_CR22","unstructured":"Mancini I, Durman JC, Toth C, et al (2002) Short-term treatment with the bisphosphonate ibandronate for opioid-resistant metastatic bone pain (abstract). Bone 30[Suppl 3]:51"},{"key":"2001_CR23","first-page":"396","volume":"11","author":"Ohlmann","year":"2003","unstructured":"Ohlmann C, Heidenreich A (2003) Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer (abstract). Support Care Cancer 11:396.","journal-title":"Support Care Cancer"},{"key":"2001_CR24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"Chesnut","year":"2004","unstructured":"Chesnut CH, Skag A, Christiansen C, et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"2001_CR25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","volume":"19","author":"Ravn","year":"1996","unstructured":"Ravn P, Clemmesen B, Riis BJ, Christiansen C (1996) The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomised, double-blind, placebo-controlled, dose-finding study. Bone 19:527\u2013533","journal-title":"Bone"},{"key":"2001_CR26","doi-asserted-by":"crossref","unstructured":"Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001;16:1871\u20131878","DOI":"10.1359\/jbmr.2001.16.10.1871"},{"key":"2001_CR27","doi-asserted-by":"crossref","unstructured":"Cooper C, Emkey RD, McDonald RH, et al (2003) Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 88:4609\u20134615","DOI":"10.1210\/jc.2003-022029"},{"key":"2001_CR28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","volume":"103","author":"Thi","year":"1997","unstructured":"Thi\u00e9baud D, Burckhardt P, Kriegbaum H, et al (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298\u2013307","journal-title":"Am J Med"},{"key":"2001_CR29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","volume":"34","author":"Adami","year":"2004","unstructured":"Adami S, Felsenberg D, Christiansen C, et al (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34:881\u2013889","journal-title":"Bone"},{"key":"2001_CR30","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","volume":"34","author":"Recker","year":"2004","unstructured":"Recker R, Stakkestad JA, Chesnut CH, et al (2004) Clinical assessment of intravenous ibandronate injection once every 3 months in postmenopausal osteoporosis. Bone 34:890\u2013899","journal-title":"Bone"},{"key":"2001_CR31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","volume":"19","author":"McClung","year":"2004","unstructured":"McClung MR, Wasnich RD, Recker R, et al (2004) Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 19:11\u201318","journal-title":"J Bone Miner Res"},{"key":"2001_CR32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01174.x","volume":"254","author":"Tanko","year":"2003","unstructured":"Tanko LB, Felsenberg D, Czerwinski E, et al (2003) Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 254:159\u2013167","journal-title":"J Intern Med"},{"key":"2001_CR33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","volume":"62","author":"Stakkestad","year":"2003","unstructured":"Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al (2003) Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 62:969\u2013975","journal-title":"Ann Rheum Dis"},{"key":"2001_CR34","unstructured":"Recker RR, Reid DM, Sambrook P, et al (2004) Intermittent intravenous ibandronate injection regimens provide at least equivalent efficacy to daily oral ibandronate: 1-year results from DIVA. Arthritis Rheum 50(Suppl.):4095"},{"key":"2001_CR35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0149-2918(03)90005-1","volume":"25","author":"Schimmer","year":"2003","unstructured":"Schimmer RC, Bauss F (2003) Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 25:19\u201334","journal-title":"Clin Ther"},{"key":"2001_CR36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber J, Ibach K, Sorenson F (2003) Intermittent IV ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14:801\u2013807","journal-title":"Osteoporos Int"},{"key":"2001_CR37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","volume":"15","author":"Bauss","year":"2004","unstructured":"Bauss F, Russell RGG (2004) Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423\u2013433","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-005-2001-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-005-2001-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-005-2001-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T23:13:07Z","timestamp":1706656387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-005-2001-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,14]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1007\/s00198-005-2001-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,14]]}}}